Eyetech News
Most Popular Eyetech Story
OSI looks to unload Macugen, exit eye diseases
Just a year after buying Macugen from Eyetech (a 2003 Fierce 15 company), OSI Pharmaceuticals is looking for a way out of the eye disease sector. The company reports that it is exploring licensing or selling Macugen and its research assets in the field. Analysts expect OSI to shift its attention to its pipeline, which includes a promising therapy for …
... Read more...Latest Headlines
- October 1, 2009
- August 13, 2007
- November 6, 2006
- November 1, 2006
- July 2, 2006
- November 10, 2005
- September 6, 2005
- August 21, 2005
- June 21, 2005
- June 8, 2005
- May 23, 2005
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
